Douglas Yee

Douglas Yee, MD is a Professor of Medicine and Pharmacology at the University of Minnesota and Director of the Masonic Cancer Center. His research focuses on the regulation of cancer cells by insulin and insulin-like growth factors (IGFs), particularly in breast cancer.

• Affiliation: Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School.
• Research: Investigates IGF signaling pathways, the role of the fetal isoform of the insulin receptor (IR-A) in breast cancer, and strategies to target IR-A without affecting the adult isoform (IR-B).
• Clinical Trials: Leads studies in the I-SPY2 platform to evaluate neoadjuvant therapies, biomarkers, and drug combinations for breast cancer.

Research Trends: Recent work includes immune subtyping for immunotherapy response, circulating tumor DNA as a biomarker, and overcoming resistance mechanisms in HER2-negative and hormone receptor-positive cancers. His lab also explores the interplay between endocrine therapy, insulin signaling, and tumor progression.

Labs: The Yee Lab collaborates with other teams (e.g., Allred, Lange, Sachs Labs) within the Masonic Cancer Center to advance breast cancer research and therapeutic strategies.